<DOC>
	<DOCNO>NCT02590263</DOCNO>
	<brief_summary>This study seek evaluate tolerability , pharmacokinetics ( PK ) , efficacy , safety ABT-414 Japanese participant newly diagnose recurrent , World Health Organization ( WHO ) grade III IV malignant glioma .</brief_summary>
	<brief_title>Study Evaluating ABT-414 Japanese Subjects With Malignant Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Japanese participant WHO grade III IV malignant glioma Phase 1 portion WHO grade IV GBM Phase 2 portion 70 Karnofsky Performance Status Arm A Phase 1 portion Phase 2 portion 80 Karnofsky Performance Status Arm B Phase 1 portion Adequate bone marrow function Recurrent malignant glioma per RANO criterion Arm A Phase 1 portion Phase 2 portion Histologically prove newly diagnose malignant glioma Arm B Phase 1 portion Participants must confirm EGFR amplification central lab Phase 2 portion Anticancer treatment 28 day prior study Day 1 Arm A Phase 1 portion Phase 2 portion ( except temozolomide therapy newly diagnose treatment Phase 2 portion ) Anticancer treatment prior study Day 1 Arm B Phase 1 portion Participant receive prior treatment bevacizumab , recurrent glioblastoma , EGFR therapy secondary grade IV GBM Phase 2 portion Participant history major immunologic reaction Immunoglobulin G contain agent component ABT414 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>WHO grade III</keyword>
	<keyword>WHO grade IV</keyword>
</DOC>